sur EUROMEDIS GROUPE (EPA:ALEMG)
Analysis of the Euromedis Laboratories Half-Year Financial Report as of June 30, 2024
Laboratoires Euromedis has presented its financial results for the first half of 2024. These accounts, approved by the Board of Directors on October 25, 2024, show an increase in net sales to €18.3 million, up from €17.2 million in 2023 at constant scope. However, despite an improvement in the gross margin rate to 29%, profitability is under pressure from the increase in transport costs linked to the geopolitical context.
The group continued its reorganization with the integration of new digital tools, strengthening its positions in its original businesses. This strategic transformation is supported by recent successes in calls for tenders. However, the uncertain geopolitical environment, influencing maritime transport and certain raw materials, is delaying the profitability forecasts initially planned for 2024.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de EUROMEDIS GROUPE